Pain Management Drugs Market Size - By Drug Class, Indication, Pain Type, Distribution Channel, Global Forecast

List of Tables

Global Pain Management Drugs Market size is poised to record 4.5% CAGR from 2023-2032.

The scaling R&D investments by pharmaceutical companies for creating novel pain management drugs and formulations for enhanced efficacy and reduced side effects will drive the industry growth. To cite an instance, in July 2023, EuroAPI's controlled substance unit Francopia invested $76 million in a project for boosting the production of pain relief active pharmaceutical ingredients at its plant in Vertolaye, France. The growing innovations in drug delivery systems to improve the effectiveness as well as safety of pain medications will also influence the product demand.

The overall pain management drugs market is segmented based on drug class, indication, pain type, distribution channel, and region.

In terms of indication, the pain management drugs industry from the arthritic pain segment may record appreciable CAGR from 2023-2032. This is due to the rising need to alleviate and eliminate pain associated with arthritis. According to the Office of Disease Prevention and Health Promotion, the number of arthritis-affected adults is projected to rise to 78.4 million by 2040. Hence, the increasing usage of pain management drugs for arthritic pain to limit the discomfort and enhance the quality of life will add to the market growth.

On the basis of distribution channel, the market value from the online pharmacies segment is expected to expand up to 2032. The growth can be attributed to the growing preference for online pharmacies as they offer convenience, accessibility, and wide range of pain relief medications to consumers seeking relief from several types of pain. The increasing integration with telemedicine services to enable patients to consult with healthcare providers online as well as receive prescriptions will also contribute to the segment expansion.

Regionally, APAC pain management drugs market size is projected to record notable CAGR through 2032 due to the rising emphasis on patient-centric care and higher technological advancements, such as neuromodulation techniques. Increasing improvements in healthcare infrastructure as well as access to medical services has led to better diagnosis and treatment of pain conditions in the region, further driving the preference for pain management drugs.

Product Code: 6231

Chapter 1 Methodology & Scope

1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
- 1.6.1 Secondary
  - 1.6.1.1 Paid sources
  - 1.6.1.2 Public sources
- 1.6.2 Primary

Chapter 2 Executive Summary

2.1 Pain management drugs market 360 degree synopsis, 2018 - 2032 (USD Million)
- 2.1.1 Business trends
- 2.1.2 Region trends
- 2.1.3 Drug class trends
- 2.1.4 Indication trends
- 2.1.5 Pain type trends
- 2.1.6 Distribution channel trends

Chapter 3 Pain Management Drugs Market Insights

3.1 Industry landscape, 2018 - 2032 (USD Million)
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rise in incidences of chronic pain
  - 3.2.1.2 Increasing number of surgical procedures
  - 3.2.1.3 Increasing demand for non-opioid analgesics
  - 3.2.1.4 Increase in geriatric population
  - 3.2.1.5 Favorable regulatory scenario
  - 3.2.1.6 Technological advancements in drug delivery
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects and safety concerns
  - 3.2.2.2 Patent expirations and generic competition
  - 3.2.2.3 Availability of alternative therapies and non-pharmacological approaches
  - 3.2.2.4 High development costs and lengthy approval processes
3.3 Growth potential analysis
- 3.3.1 By drug class
- 3.3.2 By indication
- 3.3.3 By pain type
- 3.3.4 By distribution channel
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Global company market share analysis, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022

Chapter 5 Pain Management Drugs Market Estimates and Forecast, By Drug Class (USD Million)

5.1 Key trends, by drug class
5.2 NSAIDS
5.3 Anesthetics
5.4 Anticonvulsants
5.5 Antimigraine drugs
5.6 Antidepressant drugs
5.7 Opioids
5.8 Non-narcotic analgesics
5.9 Other drugs

Chapter 6 Pain Management Drugs Market Estimates and Forecast, By Indication (USD Million)

6.1 Key trends, by indication
6.2 Arthritic pain
6.3 Neuropathic pain
6.4 Cancer pain
6.5 Chronic back pain
6.6 Post-operative pain
6.7 Migraine
6.8 Fibromyalgia
6.9 Bone fracture
6.10 Muscle sprain/strain
6.11 Acute appendicitis
6.12 Other indications

Chapter 7 Pain Management Drugs Market Estimates and Forecast, By Pain Type (USD Million)

7.1 Key trends, by pain type
7.2 Chronic pain
7.3 Acute pain

Chapter 8 Pain Management Drugs Market Estimates and Forecast, By Distribution Type (USD Million)

8.1 Key trends, by distribution channel
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Pain Management Drugs Market Estimates and Forecast, By Region (USD Million)

9.1 North America
- 9.1.1 U.S.
- 9.1.2 Canada
9.2 Europe
- 9.2.1 Germany
- 9.2.2 UK
- 9.2.3 France
- 9.2.4 Spain
- 9.2.5 Italy
- 9.2.6 Rest of Europe
9.3 Asia Pacific
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 Australia
- 9.3.5 Rest of Asia Pacific
9.4 Latin America
- 9.4.1 Brazil
- 9.4.2 Mexico
- 9.4.3 Rest of Latin America
9.5 Middle East & Africa
- 9.5.1 South Africa
- 9.5.2 Saudi Arabia
- 9.5.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

10.1 ENDO HEALTH SOLUTIONS, INC.
10.2 Merck & Co., Inc.
10.3 Novartis AG
10.4 Pfizer, Inc.
10.5 Sanofi S.A.
10.6 Mylan N.V.
10.7 Teva Pharmaceutical Industries Ltd.
10.8 Ely Lilly and Company
10.9 Abbott Laboratories
10.10 Purdue Pharma L.P.
10.11 GlaxoSmithKline Plc
10.12 Johnson & Johnson
10.13 F. Hoffmann La Roche Ltd.